Brett Giffin, MBA
Chief Executive Officer
Mr. Giffin has more than 30 years of executive experience leading and managing healthcare companies ranging from venture-backed start-ups to global market leaders in coagulation diagnostics, including having served as Chief Commercial Officer of T2 Biosystems, CEO of Fibronostics, President and CEO of 3si Systems and Chief Commercial Officer of Accriva Diagnostics (now Werfen). Previously, he held various sales, marketing and business development roles at Drager Medical, Mallinckrodt (Medtronic), Boston Scientific and Johnson & Johnson. Mr. Giffin began his career as an U.S. Army officer serving in combat unit leadership roles throughout Central America. He holds an MBA from University of Phoenix and a BA from the College of William & Mary, where he was also a Distinguished Military Graduate.
Jarrod Niebloom, JD
President and Executive Chairman
Mr. Niebloom is the Managing Partner and Executive Chairman of Meadowbrook Capital, LLC, and was formerly the CEO of Coagulo. Previously, he was a faculty member at the Harvard Law School and advised global corporations, federal and state government officials and other high-profile clients on a range of constitutional and complex legal matters, including antitrust, various aspects of federal justiciability doctrine, preemption and a host of federal statutory and administrative issues. He has worked with litigants and counsel in cases before the U.S. Supreme Court and has authored the law treatise, Constitutional Principles, Antitrust Theory. Mr. Niebloom earned a JD from Harvard Law School, and a BA in Quantitative Economics and Political Theory from Tufts University.
Galit Frydman, DVM, ScD
Chief Science Officer
Dr. Frydman holds positions in the Division of Trauma, Emergency Surgery and Surgical Critical Care at the Massachusetts General Hospital and in the Center for Biomedical Engineering at the Massachusetts Institute of Technology, where she specializes in coagulopathies and immunothrombosis. Dr. Frydman has completed several fellowships at MIT, HMS and MGH, where she developed Coagulo’s platform technology. She has published numerous papers and book chapters on coagulation, platelet physiology, immunothrombosis and stem cell biology. Dr. Frydman earned a ScD in Biological Engineering from MIT, a DVM from the University of Florida, and a BS in Biology from Carnegie Mellon University.
Barry Berger, MD, FCAP
Chief Medical Officer
Dr. Berger served as CMO at Exact Sciences Corp. for over 20 years, where he was responsible for key strategic collaborations with academic, research, clinical, political, medical, professional and patient advocacy groups and spearheaded regulatory and reimbursement strategy. Before joining Exact, Dr. Berger was the Chair of Pathology and Laboratory Medicine at Harvard Pilgrim Healthcare, Associate Director of Pathology and Laboratory Medicine at Harvard Community Health Plan and a faculty member in Pathology at Harvard Medical School. Dr. Berger completed his residency in Pathology at Brigham and Women’s Hospital and received his MD from UPenn and his BS in Biology from the University of Miami.
Marcia Zucker, PhD
Head of Regulatory Affairs
Dr. Zucker is an expert in medical diagnostics, specializing in coagulation. Dr. Zucker is a fellow of the AACC, where she has served as Chair of the Critical and Point-of-Care Testing Division, and is a member of the CLSI for Point-of-Care Testing. Previously, Dr. Zucker was the Director of Clinical Research at ITC, where she focused on point-of-care in vitro diagnostics and led teams in clinical, regulatory, marketing, QA and sales as well as risk assessment activities (FMEA) and acting as the “voice of the customer” on new product development. Dr. Zucker earned her PhD in Molecular Biology from Princeton University and her BS in Biology from Rennselaer Polytechnic Institute.
